The Rett Syndrome Research Trust (RSRT) is proud to announce its
partnership with PMD Solutions, a leading provider of innovative
healthcare technologies, in their upcoming biosensor validation
study called VIBRANT. PMD Solutions will generously donate their
state-of-the-art RespiraSense devices and advanced analytics to
support RSRT's efforts in assessing autonomic dysfunction in
individuals with Rett syndrome, utilizing cutting-edge digital
technologies.
TRUMBULL, Conn., March 28,
2024 /PRNewswire-PRWeb/ -- The Rett Syndrome
Research Trust (RSRT) is proud to announce its partnership with PMD
Solutions, a leading provider of innovative healthcare
technologies, in their upcoming biosensor validation study called
VIBRANT. PMD Solutions will generously donate their
state-of-the-art RespiraSense devices and advanced analytics to
support RSRT's efforts in assessing autonomic dysfunction in
individuals with Rett syndrome, utilizing cutting-edge digital
technologies.
At PMD Solutions, we are committed to
leveraging our technological expertise to improve healthcare
outcomes. By providing RespiraSense devices and analytics, we aim
to advance RSRT's research efforts, enhance understanding of
autonomic dysfunction in Rett, and support faster development of a
cure.
Rett syndrome is a rare neurodevelopmental disorder that
primarily affects girls, causing severe impairments. Autonomic
dysfunction is a significant challenge faced by individuals with
Rett syndrome, impacting their breathing patterns, heart rate
variability, sleep, and overall health. RSRT's VIBRANT study aims
to validate novel solutions to monitor autonomic dysfunction using
innovative digital technologies. The ultimate goal of RSRT's
biosensor development program is to develop direct and objective
measures of symptoms that support and expedite the clinical
development of curative therapeutics.
PMD Solutions' RespiraSense devices are highly advanced wearable
sensors designed to objectively monitor and analyze respiratory
patterns. These FDA-cleared non-intrusive and user-friendly devices
provide real-time data on respiratory rate, tidal volume, and other
important parameters. The integration of RespiraSense devices with
PMD Solutions' cutting-edge analytics offers a comprehensive
solution for tracking and analyzing breathing parameters in Rett
syndrome patients.
By donating RespiraSense devices and analytics for RSRT's
biosensor validation study, PMD Solutions will contribute
significantly to the advancement of RSRT's mission to cure Rett
syndrome. "We are thrilled to partner with the Rett Syndrome
Research Trust in their innovative VIBRANT study," said
Myles Murray, Founder and CEO at PMD
Solutions. "At PMD Solutions, we are committed to leveraging our
technological expertise to improve healthcare outcomes. By
providing our RespiraSense devices and analytics, we aim to advance
RSRT's research efforts, enhance their understanding of autonomic
dysfunction in Rett syndrome, and support faster development of a
cure for Rett syndrome."
RSRT's Chief Scientific Officer, Jana
von Hehn, PhD, who will oversee the study is coordinating
the use of several innovative devices to maximize the impact of the
study. "We are thrilled that PMD Solutions will contribute in such
a meaningful and selfless way, said Dr. von Hehn. "PMD Solutions is
dedicated to serving patients and we are excited to align on this
mission for Rett."
In addition to PMD Solutions, Emerald Innovations is supporting
the study with their "invisibles" sensor technology. The Emerald
sensor gathers data without body contact, relying on radio signals
in the home for continuous monitoring, and utilizes artificial
intelligence (AI) to assess and characterize sleep, breathing, and
movement for individuals with Rett. VivoSense, Inc who has assisted
RSRT to define breathing abnormalities and deduce breathing from
ECG signals is also involved. The lab of Gari Clifford, DPhil, at
Emory University and the Georgia Institute of Technology, who are experts in
biomedical informatics, have assessed breathing and heart rate
variability in prior studies and have linked Rett disease severity
to unusual deceleration capacity, will continue to collaborate on
this study. The PMD Solutions team is testing the FDA-cleared
RespiraSense breathing patch for the first time in Rett and will
expand their use case. The Vivalink team who is providing the
FDA-cleared Multi-Vital ECG patch and Viatom Kids O2 pulse oximeter
ring to target heart rate parameters and oxygen saturation as
autonomic symptoms in addition to breathing, will round out the
collaboration.
Data generated from the study's attended in-lab overnight
polysomnogram, serving as the gold standard comparator for all
devices, will assist PMD Solutions' expansion of RespiraSense to
pediatric populations and at-home use. This significant
collaboration showcases the dedication of PMD Solutions and RSRT to
advance cutting-edge research. The collective expertise of PMD
Solutions, RSRT, Emerald Innovations, The Clifford lab, VivoSense,
and Vivalink, promises to unlock new insights into autonomic
dysfunction, paving the way for improved measurement of Rett
syndrome symptoms in therapeutic development, and expediting a cure
for Rett.
About PMD Solutions
PMD Device Solutions AB develops and sells medical products for
respiratory monitoring in both the hospital and homecare setting.
Its primary product is RespiraSense, a solution used for monitoring
respiratory rate to detect deterioration of a patient's general
condition early and to avoid preventable respiratory failure and
adverse patient outcomes. RespiraSense is, to the Company's
knowledge, the world's only continuous, motion-tolerant respiratory
rate monitor delivering class-leading reliability in measuring
respiratory rate. RespiraSense is a novel technology that is
commercialized in Europe, the UK,
and FDA cleared in the US. For additional information please visit
pmd-solutions.com.
About Emerald Innovations, Inc.
Emerald Innovations is a health analytics company that
specializes in digital health solutions for passive, contactless
in-home monitoring. Emerald seamlessly captures continuous health
data from patients as they go about their normal lives. The
Emerald DHT sensors fall under a cutting-edge category known as
Invisibles. Installed in the homes of study participants, these
sensors continuously analyze surrounding radio signals. Using
artificial intelligence, they extract patient physiological data
while prioritizing their privacy. Emerald simplifies clinical
trials for its clients by obtaining statistically significant
biomarkers, making them readily available to clinicians and data
analysts, and consistently providing updates on the progress of
clinical trials. Emerald's clientele encompasses big pharma,
Fortune 500 pharmaceutical firms, innovative biotech companies, and
leading disease research foundations. For further details, please
visit emeraldinno.com.
About the Rett Syndrome Research Trust
RSRT is the patient advocacy organization working to cure Rett
syndrome. As the largest funder of Rett syndrome research
worldwide, RSRT has played a vital role in initiating and evolving
the trajectory of progress toward a cure. All genetic therapies in
development by biopharmaceutical companies have leveraged
discoveries and resources made possible by RSRT. Learn more at
reverserett.org.
About Rett Syndrome
Rett syndrome is a genetic childhood neurological disorder
caused by random mutations of the MECP2 gene on the X chromosome.
The disorder affects predominantly girls but can rarely also affect
boys. Symptoms typically become apparent between the ages of 12 to
18 months. Rett syndrome is devastating as it deprives toddlers of
speech, hand use, and normal movement often including the ability
to walk. As childhood progresses the disorder brings anxiety,
seizures, tremors, breathing difficulties, and severe
gastrointestinal issues. While their bodies suffer, it is believed
that their cognitive abilities remain largely intact. Although most
children survive to adulthood, they require total round- the-clock
care.
Media Contact
Monica Coenraads, Rett Syndrome
Research Trust, 1 2034450041, monica@rsrt.org,
https://reverserett.org/
View original
content:https://www.prweb.com/releases/pmd-solutions-supports-rsrts-biosensor-vibrant-study-for-rett-syndrome-with-donation-of-fda-cleared-respirasense-devices-and-analytics-302102170.html
SOURCE Rett Syndrome Research Trust